Shares in Mind Medicine (MindMed; Nasdaq: MNMD) were nearly 52% higher following Thursday's trading.
The USA-based brain health biotech made a series of announcements on the day, the first two relating to its development of MM120 (lysergide d-tartrate).
Firstly, it was announced that the US Food and Drug Administration (FDA) has granted Breakthrough designation to the MM120 program for the treatment of generalized anxiety disorder (GAD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze